Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

Summary

The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).

Timeline

Start

2024-06-17

Primary completion

2026-08-01

Completion

2026-08-01

Outcome

Met primary endpoint

release “today announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO ® (vosoritide) in children with hypochondroplasia met its primary endpoint” biomarin.com ↗

release “Phase 3 CANOPY-HCH-3 study of VOXZOGO in children with hypochondroplasia met its primary endpoint” biomarin.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vosoritide	Peptide	—	Subcutaneous

Indications